SuperSonic Imagine to Feature its Non-Invasive, 60-Second Liver Exam at The Liver Meeting 2016
Attendees in Boston will see demonstrations of Aixplorer with real-time ShearWave Elastography™
and several clinical research abstracts on its use for liver stiffness measurement
Regulatory News:
SuperSonic Imagine (Paris:SSI) (Euronext: SSI, FR0010526814), a company specializing in ultrasound medical imaging, announced
today that it will feature Aixplorer with real-time ShearWave Elastography (SWE™) at The Liver Meeting 2016 November 11 - 15 in
Boston. The Company will be exhibiting in conjunction with Sandhill Scientific, Inc., their exclusive distributor in the United
States for providing the Aixplorer® ultrasound system to Gastroenterologists and Hepatologists. Attendees of this meeting, held by
the American Association for the Study of Liver Diseases (AASLD), will have the opportunity to learn more about SWE’s value to
patients with chronic liver disease.
Real-time ShearWave Elastography (SWE), available only on the Aixplorer ultrasound system, is a 60-second non-invasive exam that
can be used for imaging patients with chronic liver disease. SWE offers the advantage of a real-time image of liver anatomy, while
also providing a color coded map and quantitative measurement of liver stiffness, making it an important parameter to enhance liver
diagnostics. About 100 international publications have demonstrated the reliability and effectiveness of SuperSonic Imagine’s SWE
in this area. In addition, eight abstracts accepted by AASLD reporting results from clinical research studies using SuperSonic’s
imagine’s technology will be presented as posters during the meeting:
Diagnostic accuracy of Shear Wave Elastography for the assessment of liver stiffness in pediatric patients
with fatty liver disease (Abstract #546)
Matteo Garcovich et al.
#654 Role of shear wave elastography in patients on high dose methotrexate: A prospective study (Abstract
654)
Robert S. Rahimi et al.
Regression of Liver Fibrosis assessed by non-invasive methods in Patients with Chronic Hepatitis C who
Achieved Sustained Virologic Response after DAAs Treatment (Abstract 824)
Yana Davidov et al.
Prospective Comparison between Transient Elastography, Supersonic Shear Imaging, and ARFI Imaging for
Predicting Fibrosis in Subjects with NAFLD (Abstract 1058)
Won Kim et al.
Improvement in Non-Invasive Hepatic Parameters of Nonalcoholic Fatty Liver Disease in Obese Uncontrolled Type
2 Diabetes Mellitus Patients who underwent Endoscopic Duodenal–Jejunal Bypass Liner (Endobarrier) Implantation (Abstract 1105)
Oranit Cohen-Ezra et al.
Probiotics do not improve hepatic outcomes after Laparoscopic Sleeve Gastrectomy surgery: a randomized
clinical trial (Abstract 1123)
Shiri Sherf Dagan et al.
2-dimensional shear wave elastography rather than HVPG significantly improves MELD-Na to predict survival in
decompensated cirrhosis patients (Abstract 1406)
Maja Thiele et al.
“SuperSonic Imagine’s dedication to advancing the evaluation of chronic liver disease has enabled us to develop innovative
solutions such as image-guided ShearWave Elastography, an accurate, easy-to-use and pain-free liver exam,” explained SuperSonic
Imagine Founder and Chief Innovation Officer Jacques Souquet. “We are excited to share this technology’s capabilities at The Liver
Meeting, where we know hepatologists from around the world will share our enthusiasm for the non-invasive quantification of liver
stiffness.”
SSI will be exhibiting at booth #313 throughout The Liver Meeting.
The Liver Meeting® is a registered trademark of the American Association for the Study of Liver Diseases.
About SuperSonic Imagine
Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The
company designs, develops and markets a revolutionary ultrasound system, Aixplorer®, with an UltraFast™ platform that can acquire
images 200 times faster than conventional ultrasound systems. In addition to providing exceptional image quality, this unique
technology is the foundation of several innovations which have changed the paradigm of ultrasound imaging: ShearWave™ Elastography
(SWE™), UltraFast™ Doppler and more recently Angio PL.U.S* – Planewave UltraSensitive™ Imaging.
ShearWave Elastography allows physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible
and non-invasive manner. This criteria has become an important parameter in diagnosing potentially malignant tissue or other
diseased tissue. As of today, over 300 peer-reviewed publications have demonstrated the value of SWE for the clinical management of
patients with a wide range of diseases. UltraFast Doppler combines Color Flow Imaging and Pulsed Wave Doppler into one simple exam,
providing physicians with exam results simultaneously and helping to increase patient throughput. The latest innovation, Angio
PL.U.S, provides a new level of microvascular imaging through significantly improved color sensitivity and spatial resolution while
maintaining exceptional 2D imaging.
SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer in key global markets.
SuperSonic Imagine is a listed company since April 2014 on the Euronext, symbol SSI. For more information about SuperSonic Imagine,
please go to www.supersonicimagine.com.
*Pending FDA 510(k) clearance
SuperSonic Imagine
Bernard Doorenbos, +33 6 15 66 64 68
CEO
bernard.doorenbos@supersonicimagine.com
or
SuperSonic Imagine
Marketing & Communication
Emmanuelle Vella, +33 4 86 79 03 27
emmanuelle.vella@supersonicimagine.com
or
NewCap
Investor Relations – EU
Pierre Laurent / Florent Alba
+33144719855
supersonicimagine@newcap.fr
or
Pascale Communication
Media Relations - US
Amy Phillips, +1 412 327 9499
amy@pascalecommunications.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20161110006084/en/